Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression.
about
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in miceUnderstanding of molecular mechanisms in natural killer cell therapyThe role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-MycTranscription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunityThe polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2DSpecific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivoHistone deacetylase inhibitors for treating a spectrum of diseases not related to cancerPharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).HDAC inhibition and graft versus host diseaseThe oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.Emerging therapies in hematopoietic stem cell transplantationHistone/protein deacetylases and T-cell immune responsesRegulation of immune responses by histone deacetylase inhibitorsDeacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation.Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesisNovel findings in drug-induced dendritic cell tolerogenicity.Epigenetics of autoimmune diabetes.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?New insights into the immunopathogenesis of systemic lupus erythematosus.Beyond Genetics: What Causes Type 1 Diabetes.MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.Estrogen receptor α/HDAC/NFAT axis for delphinidin effects on proliferation and differentiation of T lymphocytes from patients with cardiovascular risks.Cytokine-induced monocyte characteristics in SLETrichostatin A attenuates airway inflammation in mouse asthma model.Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.Modulation of antitumor immunity with histone deacetylase inhibitors.Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells.Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice.Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways.
P2860
Q24288997-0E045DA5-B493-4C46-B2B1-D813D88478C9Q28086976-CB159CC2-478E-4BB9-8DFD-7DBDFAF2537EQ28299585-109270A2-AB0F-4702-B115-188A3634FD95Q28593951-EA814617-F6D4-41B2-B137-9AEDD19B69A5Q34440758-9D39C863-0C58-4461-9DF9-6D6558542527Q34467682-6264FC44-CAFE-46CD-9EA5-C091D9633EE8Q35002986-A2557C8F-0D6C-405E-8667-399124EA8F76Q35016934-E42CB5BD-1080-4810-9068-DC4E3C1BF9F0Q35016969-7E0612CF-084D-43BD-804D-CCF98E56E27CQ35016985-2BC0469B-6CFD-4C0D-95E5-F57CFD1776E9Q35017018-7A495727-41CE-42F3-99DD-1678BDF36C11Q35825522-0C5BEA4E-9B77-44B9-85E0-CFC0B966D03FQ35849307-B0838800-7C99-4E95-B6F6-9C65E1C8A841Q35855571-8E7800F3-43E1-498C-B95E-4EF7C94431CBQ36304111-B76FDA4B-0F4E-4277-9954-90B9C2B395EAQ37026059-C768193E-74CB-4C3D-A955-5A97E8B30DDBQ37095317-9ED4E65D-9A22-4B06-B816-DFEE2E6113B0Q37130888-22783C0B-3D32-41EF-80A4-C5CB046F0529Q37809070-A3EA0494-2132-440C-8456-6501FC833353Q37962602-3E9A7439-1A9B-4551-98CA-8A902705027BQ38202155-44B4BAC6-0881-4083-BA81-1C44F1D08A0DQ38568358-AE9AB4DB-9738-4547-828C-56CF36C3E5C2Q39016144-E91A1FFC-1850-438E-8420-FFD97C77D7CBQ39017669-D8834D47-7D6D-44AF-A651-6016D96F3938Q39372689-4383BA60-1E06-4FB8-882D-BE1C18B00983Q41516166-29AA132F-AA2F-4B5B-B783-E6E5A4E56B48Q42141284-BBCDBD23-0FFD-4B34-88F9-0C65652B3A02Q45222913-0CFAD881-130A-4459-8304-115C16C29B1AQ46155945-7FD5D57B-C213-42E3-A0E4-DF043F55C932Q49557954-EFA178EF-9558-4943-A8A9-3B6EEAB21F5CQ50034338-BFDABFF3-68D7-4235-9FA8-62DCFC76E785Q51504244-1FCBCAD1-C516-4426-86F6-3E2E4BF0B4BEQ54599511-789B4026-C5FC-4EC8-8B94-55A86FD8CED6
P2860
Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Histone deacetylase inhibitors ...... ssential for CD154 expression.
@en
Histone deacetylase inhibitors ...... ssential for CD154 expression.
@nl
type
label
Histone deacetylase inhibitors ...... ssential for CD154 expression.
@en
Histone deacetylase inhibitors ...... ssential for CD154 expression.
@nl
prefLabel
Histone deacetylase inhibitors ...... ssential for CD154 expression.
@en
Histone deacetylase inhibitors ...... ssential for CD154 expression.
@nl
P2093
P1433
P1476
Histone deacetylase inhibitors ...... ssential for CD154 expression.
@en
P2093
Birgitte K Michelsen
Klaus Rieneck
Kresten Skak
Lone Frier Bovin
Niels Ødum
Søren Skov
Søren Tomra
P304
P356
10.1182/BLOOD-2002-07-2073
P407
P577
2002-10-17T00:00:00Z